UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2006-02, Vol.354 (6), p.567-578

2006

Volltextzugriff (PDF)

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

Annual review of medicine, 2004-01, Vol.55 (1), p.433-457

Rowinsky, Eric K

2004

Volltextzugriff (PDF)

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Volltextzugriff (PDF)

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Investigational new drugs, 2020-10, Vol.38 (5), p.1448-1453

2020

Volltextzugriff (PDF)

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Blood, 2014-07, Vol.124 (3), p.385-392

2014

Volltextzugriff (PDF)

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

Haematologica (Roma), 2015-02, Vol.100 (2), p.223-230

2015

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Cancer, 2010-02, Vol.116 (4), p.1027-1032

2010

Volltextzugriff (PDF)

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

Annual review of medicine, 1997-01, Vol.48 (1), p.353-374

Rowinsky, MD, Eric K

1997

Volltextzugriff (PDF)

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

British journal of haematology, 2014-09, Vol.166 (6), p.862-874

2014

Volltextzugriff (PDF)

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

Oncogene, 2000-12, Vol.19 (56), p.6680-6686

2000

Volltextzugriff (PDF)

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

JAMA oncology, 2024-09

2024

Volltextzugriff (PDF)

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Clinical and translational science, 2024-03, Vol.17 (3), p.e13750-n/a

2024

Volltextzugriff (PDF)

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

The oncologist (Dayton, Ohio), 2003-12, Vol.8 (S3), p.5-17

Rowinsky, Eric K.

2003

Volltextzugriff (PDF)

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Cancer, 2010-02, Vol.116 (S4), p.1018-1026

2010

Volltextzugriff (PDF)

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

JNCI : Journal of the National Cancer Institute, 2002-12, Vol.94 (24), p.1883-1888

2002

Volltextzugriff (PDF)

mTOR Inhibition for Cancer Therapy: Past, Present and Future

1st ed. 2016, 2016

Volltextzugriff (PDF)

Paclitaxel (Taxol)

The New England journal of medicine, 1995-04, Vol.332 (15), p.1004-1014

1995

Volltextzugriff (PDF)

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Investigational new drugs, 2012-08, Vol.30 (4), p.1597-1606

2012

Volltextzugriff (PDF)

Vascular endothelial growth factor receptor‐1 in human cancer

Cancer, 2010-02, Vol.116 (S4), p.1027-1032

2010

Volltextzugriff (PDF)

Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer

Clinical breast cancer, 2003-06, Vol.4 (2), p.126-137

2003

Volltextzugriff (PDF)

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

Cancer, 2010-02, Vol.116 (S4), p.1013-1017

2010

Volltextzugriff (PDF)

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Investigational new drugs, 2010-06, Vol.28 (3), p.334-342

2010

Volltextzugriff (PDF)

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

Investigational new drugs, 2011-06, Vol.29 (3), p.481-488

2011

Volltextzugriff (PDF)

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

Investigational new drugs, 2011-02, Vol.29 (1), p.167-174

2011

Volltextzugriff (PDF)

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

Investigational new drugs, 2007-08, Vol.25 (4), p.359-367

2007

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Zeitschrift / SerieClinical Cancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(149)
Mit Volltextzugriff
(156)

Publikationsform

Sprache

Englisch
(167)

Erscheinungsjahr

n.n

Thema

Humans
(84)
Oncology
(68)
Life Sciences & Biomedicine
(67)
Science & Technology
(67)
Biological And Medical Sciences
(47)
Medical Sciences
(47)
Antineoplastic Agents
(42)
Pharmacology. Drug Treatments
(40)
Female
(39)
Male
(35)
Adult
(33)
Middle Aged
(33)
Aged
(32)
Chemotherapy
(32)
Antineoplastic Agents - Therapeutic Use
(28)
Neoplasms - Drug Therapy
(24)
Cancer
(19)
Medical Research
(19)
Tumors
(19)
Animals
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

mTOR Inhibition for Cancer Therapy: Past, Present and Future

Paclitaxel (Taxol)

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Vascular endothelial growth factor receptor‐1 in human cancer

Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

Aktive Filter

Suchergebnisse filtern